Shahram Salek-Ardakani
2021
In 2021, Shahram Salek-Ardakani earned a total compensation of $4M as Chief Scientific Officer at Janux Therapeutics.
Compensation breakdown
| Bonus | $125,000 |
|---|---|
| Non-Equity Incentive Plan | $56,818 |
| Option Awards | $3,638,223 |
| Salary | $189,394 |
| Total | $4,009,435 |
Salek-Ardakani received $3.6M in option awards, accounting for 91% of the total pay in 2021.
Salek-Ardakani also received $125K in bonus, $56.8K in non-equity incentive plan and $189.4K in salary.
Rankings
In 2021, Shahram Salek-Ardakani's compensation ranked 3,342nd out of 12,415 executives tracked by ExecPay. In other words, Salek-Ardakani earned more than 73.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,342 out of 12,415 | 73rd |
Division Manufacturing | 1,358 out of 5,508 | 75th |
Major group Chemicals And Allied Products | 553 out of 2,378 | 77th |
Industry group Drugs | 492 out of 2,099 | 77th |
Industry Pharmaceutical Preparations | 340 out of 1,549 | 78th |
Source: SEC filing on April 29, 2022.
Salek-Ardakani's colleagues
We found two more compensation records of executives who worked with Shahram Salek-Ardakani at Janux Therapeutics in 2021.